Conformation-Selective PI3Kδ Inhibitor Roginolisib Shows Safety And

Roginolisib: What Two New Studies Tell Us—and What They Don’t Yet Show

Two papers published in Nature Communications report new findings about roginolisib, an experimental cancer drug being developed by iOnctura. One study describes how the drug interacts with a cancer-related enzyme called PI3Kδ. The other reports results from an early clinical trial involving people with advanced cancers. The findings may be meaningful for people facing hard-to-treat […]

Conformation-Selective PI3Kδ Inhibitor Roginolisib Shows Safety and

A first-in-human trial shows that the conformation-selective PI3Kδ inhibitor roginolisib is well tolerated in advanced cancers and is associated with median overall survival of up to 20.8 months in metastatic uveal melanoma, alongside immune changes consistent with relief of tumour-induced immunosuppression.

A promising new chapter for PI3Kδ inhibition: Nature Communications publications reveal novel mechanism behind iOnctura's roginolisib

• First publication reveals how roginolisib uniquely locks the cancer-driving enzyme PI3Kδ in an inactive state, differentiating the drug from other PI3Kδ inhibitors • Second publication outlines first-in-human (FiH) study results, demonstrating roginolisib’s favorable tolerability profile and encouraging clinical findings in patients with cancer, including metastatic uveal melanoma (mUM) • Publication of the peer-reviewed papers […]